



Module 1.3.2 Consumer Medicine Information (CMI)

Lenalidomide Devatis

2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg & 25 mg Capsules

Lenalidomide

Consumer Medicine Information (CMI)

What is in this leaflet

please read this leaflet carefully before you start using Lenalidomide Devatis Capsules.

This leaflet answers some common questions about Lenalidomide Devatis Capsules. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Lenalidomide Devatis Capsules against the benefits this medicine is expected to have for you.

If you have any concerns about taking Lenalidomide Devatis Capsules, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What Lenalidomide Devatis Capsules is used for

LENALIDOMIDE Devatis Capsules contain an active substance called lenalidomide. Lenalidomide belongs to a group of medicines called immunomodulating agents that work by acting on the cells involved in the body's immune system. The immune system is part of the body's defence which helps to fight illness and infection.

Treatment of Multiple Myeloma

Multiple myeloma (MM) is a cancer of the bone marrow.

- Lenalidomide Devatis is used to treat adult patients who have been diagnosed with newly diagnosed Multiple Myeloma (NDMM) and who have undergone a stem cell transplant.
- Lenalidomide Devatis is used in combination with another medicine called dexamethasone to treat adult NDMM patients who are not eligible for stem cell transplantation.
- Lenalidomide Devatis is also used in combination with dexamethasone to treat adult MM patients whose disease has progressed after one therapy.

Treatment of Myelodysplastic Syndromes

Lenalidomide Devatis is also used to treat patients who have conditions called myelodysplastic syndromes (MDS) in whom the bone marrow does not produce enough mature blood cells. This causes a lack of healthy blood cells in the body. There are different types of MDS.

Lenalidomide Devatis is approved to treat a type of MDS where part of chromosome 5 is missing. This type of MDS is known as deletion 5q MDS (or 5q minus). Patients with this type of MDS often have low red blood cell counts that require treatment with blood transfusions. It is hoped that the use of Lenalidomide Devatis will reduce the need for blood transfusions.

Ask your doctor if you have any questions about how Lenalidomide Devatis works, or why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

This medicine is not addictive.

Lenalidomide Devatis will only be prescribed to you by a doctor who has experience in medicines to treat cancers of the blood.





Module 1.3.2 Consumer Medicine Information (CMI)

Before you take Lenalidomide Devatis Capsules

When you must not take it

Do not take this medicine if you are pregnant, or think that you may be pregnant, or planning to become pregnant.

Lenalidomide Devatis may cause birth defects (deformed babies), and may affect your developing baby if you take it during pregnancy.

Do not take this medicine if you are able to become pregnant, unless you are willing to follow the required pregnancy prevention measures (outlined in restricted distribution program – see section 'Before you start to take it').

If you are not sure whether you should start taking this medicine, talk to your doctor.

Do not take Lenalidomide Devatis if you have an allergy to lenalidomide or any of the other ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic response may include:

- shortness of breath
- wheezing or difficulty breathing
- swelling of the face, lips, tongue or other parts of the body
- rash, itching or hives on the skin.

If you think you may be allergic to Lenalidomide Devatis, ask your doctor for advice.

Before you start to take it

Follow your doctor's instructions carefully.

You will have been given specific instructions by your doctor particularly on the potential effects of lenalidomide on unborn babies.

If you have not fully understood these instructions, ask your doctor again before taking Lenalidomide Devatis.

Your doctor will have enrolled you in the *Restricted Distribution Program* to ensure that lenalidomide is used safely.

The Restricted Distribution Program

Lenalidomide is structurally related to 'thalidomide', which is known to cause severe life-threatening human birth defects (deformed babies) and can cause death to an unborn baby if taken during pregnancy. If Lenalidomide Devatis is taken during pregnancy, it may cause birth defects or death to an unborn baby.

To avoid exposure to unborn babies, Lenalidomide Devatis is available only under a special distribution program called the *Restricted Distribution Program*. This program is designed to ensure that Lenalidomide Devatis is always prescribed and taken in the recommended way. Importantly, only patients who are formally enrolled in this program and agree to fully comply with all the requirements of this program can receive Lenalidomide Devatis.

Some of the requirements of the *Restricted Distribution Program* are outlined in the following sections. Your doctor will discuss all the details with you.

1. For women taking Lenalidomide Devatis


Before starting this treatment, your doctor will discuss your potential to become pregnant, even if you think this is unlikely e.g. if your periods have stopped.

If you are able to become pregnant:

DEVATIS LIMITED Property-Strictly confidential Version: V01/May 2022



Lenalidomide Devatis 2.5 mg, 5 mg, 7.5 mg, 10 mg,





Module 1.3.2 Consumer Medicine Information (CMI)

- Your doctor will discuss the potential risk to unborn babies if Lenalidomide Devatis is taken during pregnancy.
- You will be required to have pregnancy tests before treatment, every 4 weeks during treatment, and 4 weeks after stopping treatment.
- You should start your Lenalidomide Devatis treatment as soon as you get it from the pharmacy following a negative pregnancy test.
- Use reliable means of contraception for at least 4 weeks before starting Lenalidomide Devatis treatment, during treatment and treatment interruption, and for at least 4 weeks after Lenalidomide Devatis treatment has stopped.

Your doctor will tell you what method of contraception to use.

Effective methods of contraception include the following:

- Implant
- Levonorgestrel-releasing intrauterine system (IUS)
- Medroxyprogesterone acetate depot
- Tubal ligation
- Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
- Ovulation inhibitory progesterone-only pills (i.e. desogestrel).

Combined oral contraceptive pills are not recommended as they can increase the risk of blood clots blocking blood vessels in patients with MM being treated with this medicine.

You must stop taking Lenalidomide Devatis and inform your doctor straight away if:

- You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant.
- You have heterosexual intercourse without using reliable means of contraception.

Discuss with your doctor if you should breast-feed whilst taking this medicine.

It is not known if Lenalidomide Devatis is excreted in human milk. Therefore, you should discuss with your doctor whether to discontinue breast-feeding while you are receiving this medicine.

2. For men taking Lenalidomide Devatis

Before starting this treatment, discuss with your doctor if your partner is able to become pregnant. If your partner is able to become pregnant, use barrier methods of contraception (e.g. condoms) even if you are vasectomised, during Lenalidomide Devatis treatment, during treatment interruption, and for at least 1 week after treatment has stopped.

Tell your doctor immediately if your partner becomes pregnant whilst you are taking this medicine. Do not donate semen during treatment or during treatment interruption, or for 1 week after stopping treatment.

3. For all patients taking Lenalidomide Devatis

Discuss with your doctor if you have or have had any of the following medical conditions:

- Blood clots, high blood pressure or high cholesterol
- Frequent bleeding or bruising
- Frequent infections
- Hepatitis B virus infection
- Peripheral neuropathy (numbness, tingling, weakness, abnormal co-ordination or pain in your hands and
- Thyroid problems
- Abnormal kidney function
- Liver problems e.g. liver infections





Module 1.3.2 Consumer Medicine Information (CMI)

• Allergic reactions to thalidomide or lenalidomide.

If you have not told your doctor about any of the above, tell him/her before you start taking Lenalidomide Devatis.

Do not donate blood during Lenalidomide Devatis treatment or during treatment interruption, and for at least 1 week after stopping treatment.

In New Zealand, patients with certain cancers may be excluded from donating blood.

Do not take Lenalidomide Devatis if you have the rare hereditary problems of glucose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Lenalidomide Devatis contains lactose.

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Your doctor will ask you to have regular blood tests during treatment with Lenalidomide Devatis.

Your doctor should ask you to have a blood test every week for the first 8 weeks of treatment with Lenalidomide Devatis and at least every month after that. Your doctor may adjust your dose of Lenalidomide Devatis or stop your treatment based on the results of your blood tests and on your general condition. If you are older than 65 years, in addition to these blood tests, your doctor may also check your kidney function with other tests.

Do not give this medicine to a child or adolescent under the age of 18 years.

Safety and effectiveness in children younger than 18 years have not been established.

It is important to note that a small number of patients with MM may develop additional types of cancer (regardless of their type of therapy). At this stage, it cannot be excluded that this risk may be slightly increased with Lenalidomide Devatis treatment. Therefore, your doctor will carefully evaluate the benefit and risk when you are prescribed this medicine.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines or have recently taken any other medicines, including any medicines that you buy without a prescription from a pharmacy, supermarket or health-food shop.

Some medicines and Lenalidomide Devatis may interfere with each other. These include:

- medicines used to prevent pregnancy, such as oral contraceptives
- medicines used to treat symptoms of menopause e.g. hormone replacement therapy
- medicines used for heart problems e.g. digoxin
- medicines used to thin the blood e.g. warfarin.

How to take Lenalidomide Devatis Capsules

Follow all directions given to you by your doctor carefully. They may differ from the information in this leaflet.

How much to take

Your doctor will tell you how much Lenalidomide Devatis to take and for how long you will need to take it.

For the treatment of NDMM after a stem cell transplant, the usual starting dose is 10 mg once daily.

For the treatment of MM in combination with dexamethasone (either NDMM in patients not eligible for stem cell transplantation or MM in patients whose disease has progressed after one therapy), the usual starting dose is 25 mg once per day for 21 out of 28 days.





Module 1.3.2 Consumer Medicine Information (CMI)

For the treatment of MDS, the recommended starting dose is 10 mg once per day for 21 out of 28 days.

Your doctor will monitor your progress, and may adjust your dose of Lenalidomide Devatis or stop your treatment based on the results of your blood tests and on your general condition.

How to take it:

Swallow the capsules whole, preferably with water, once a day as directed by your doctor. Do not open, break or chew the capsules.

If powder from inside the capsules leaks out and contacts the skin, wash the skin immediately and thoroughly with soap and water. If lenalidomide contacts the mucous membranes e.g. the eyes, flush thoroughly with water.

When to take it:

Take your medicine either one hour before or two hours after eating food.

How long to take it:

Your doctor will tell you how long to continue taking Lenalidomide Devatis.

Continue taking Lenalidomide Devatis at about the same time each day for 21 days in a row and stop taking Lenalidomide Devatis for the next 7 days. Repeat taking Lenalidomide Devatis for 21 days and stopping for 7 days until your doctor tells you to stop.

If you forget to take Lenalidomide Devatis Capsules

If it is less than 12 hours before your next dose, skip the dose you missed and take the next dose when you are meant to.

Otherwise, take it as soon as you remember, and then go back to taking your medicine as you would normally.

Do not take a double dose to make up for the dose you missed.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering when to take your medicine, ask your pharmacist for some hints.

In case of overdose

If you take more Lenalidomide Devatis Capsules than you should (overdose)

Immediately telephone your doctor or contact the National Poisons Centre (telephone 0800 POISON or 0800 764 766) for advice, or go to the Emergency Department at your nearest hospital, if you think that you or anyone else may have taken too much Lenalidomide Devatis.

Do this even if there are no signs of discomfort or poisoning. Keep the telephone numbers for these places handy.

If you have any further questions on the use of Lenalidomide Devatis, ask your doctor or pharmacist.

While you are taking Lenalidomide Devatis Capsules

Things you must do

Female patients:

• Tell your doctor immediately if you become pregnant or suspect that you may be pregnant. You should also immediately stop taking Lenalidomide Devatis in this case.





Module 1.3.2 Consumer Medicine Information (CMI)

All patients:

- Tell any other doctors, dentists, and pharmacists who are treating you that you are taking Lenalidomide Devatis.
- If you are about to be started on any new medicine, remind your doctor, dentist or pharmacist that you are taking Lenalidomide Devatis.
- Keep all of your doctor's appointments so that your progress can be checked.

 Your doctor will do some blood tests regularly and will check your general condition to make sure the medicine is working and to prevent unwanted side effects.

Things you must not do

Female patients:

- Do not become pregnant whilst taking Lenalidomide Devatis.
- Do not have sexual intercourse without using effective means of contraception described to you by your doctor.

Male patients:

- Do not donate sperm during treatment or treatment interruption, or for at least 1 week after stopping treatment.
- Do not have sexual intercourse without using effective means of contraception described to you by your doctor.

All patients:

- Do not donate blood during treatment or treatment interruption, or for at least 1 week after stopping treatment.
 - In New Zealand, patients with some types of cancer may be excluded from donating blood.
- Do not stop taking Lenalidomide Devatis (unless you suspect that you are pregnant) or change the dose without first checking with your doctor.
- Do not let yourself run out of medicine over the weekend or on holidays.
- Do not give this medicine to anyone else, even if they have the same condition as you.
- Do not take this medicine to treat any other complaints unless your doctor or pharmacist tells you to
- Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering.
 - In that case, return it to your pharmacist.

Things to be careful of:

Be careful driving or operating machinery until you know how Lenalidomide Devatis affects you.

This medicine may cause dizziness, tiredness or blurred vision in some people. If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous.

Side effects

Tell your doctor as soon as possible if you have any problems while taking Lenalidomide Devatis Capsules, even if you do not think the problems are connected with the medicine or are not listed in this leaflet.

Like all medicines, Lenalidomide Devatis can have side effects, although not everybody gets them. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.





Module 1.3.2 Consumer Medicine Information (CMI)

Tell your doctor if you notice any of the following and they worry you:

- Diarrhoea; constipation; feeling sick (also called nausea); vomiting; stomach pain; indigestion; dehydration; dry mouth; toothache; increase or decrease in weight; increase or decrease in appetite; loss of taste.
- Itchiness; rash; redness of the skin; dry skin; excessive sweating.
- Dizziness; fainting; headache; shaking or tremors; reduced sense of touch.
- Difficulty sleeping; depression; anxiety; feeling of confusion.
- Back pain; muscle spasms; muscle and/or joint pain; swollen joints; bone pain; muscular weakness; fall.
- Swelling of hands, ankles or feet.

The above list mainly includes the more common side effects of your medicine.

Tell your doctor immediately if you notice any of the following:

• Bleeding (including nose-bleeds) or bruising more easily than normal.

Lenalidomide Devatis can reduce the number of platelets, which are responsible for making the blood clot properly. Your doctor may monitor your blood cell numbers during treatment with Lenalidomide Devatis.

• Tiredness, headaches, shortness of breath, dizziness and looking pale.

Lenalidomide Devatis can reduce the number of red blood cells that carry oxygen around the body.

• Numbness, tingling, or weakness of the arms and legs.

This may be due to nerve damage.

• Blurred vision or difficulty seeing.

This could be due to a cataract in your eye(s).

• Passing large amounts of urine, excessive thirst, and having a dry mouth and skin.

These could be symptoms of diabetes.

• Abnormal eye movements, convulsions, or irregular heart rhythms.

These could be due to low levels of minerals such as potassium, calcium, magnesium or sodium.

The above list includes serious side effects that may require medical attention.

If any of the following happens, stop taking Lenalidomide Devatis and see a doctor immediately or go to Accident and Emergency at your nearest hospital:

• Shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, mouth, tongue or other parts of the body; rash, itching or hives on the skin.

These could be symptoms of an allergic reaction.

• Severe blisters and bleeding in the lips, eyes, mouth, nose and genitals; painful red area on the skin that spreads quickly; peeling of the skin. You may have a high temperature, chills and muscle ache at the same time.

These could be due to rare but severe skin reactions such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms.

• Blurred vision; severe headache; weakness or numbness in the face, arm or leg; trouble speaking or understanding; loss of balance.

This may be due to a stroke which could be a result of blood clots in the blood vessels of your brain.

• Sudden pain in your chest or difficulty in breathing.

DEVATIS LIMITED Property-Strictly confidential

This may be due to a heart attack or blood clots in the artery leading to your lungs. These blood clots can happen during treatment, or after treatment has stopped.

• Pain or swelling in your legs, especially in your lower leg or calves.

This may be due to blood clots in the veins of your leg. These can happen during treatment, or after treatment has stopped.

• Fever; severe chills; decreased urination; rapid pulse; rapid breathing; confusion; nausea; vomiting; diarrhoea; pain or burning when you urinate; hacking cough; phlegm; sore mouth or throat; flu-like symptoms; feeling of tension in the nose, cheeks and behind your eyes; or mouth ulcers.

These could symptoms of sepsis (blood infection) or other serious infections such as pneumonia.

• Passing little or no urine; drowsiness; nausea; vomiting; or breathlessness.





Module 1.3.2 Consumer Medicine Information (CMI)

These could be symptoms of kidney disease.

• Abdominal pain, dark urine, fever, joint pain, loss of appetite, nausea and vomiting, yellowing of the skin and/or eyes.

These are symptoms of liver failure, which in some cases, may be due to Hepatitis B virus infection. Some cases of Hepatitis B virus infection may not result in symptoms initially.

The above list includes very serious side effects. You may need urgent medical attention or hospitalisation.

Tell your doctor or pharmacist immediately if any of the side effects gets serious, or if you notice any other side effects not listed in this leaflet.

Other side effects not listed above may also occur in some people.

Some of these side effects (for example, changes in thyroid function, or blood pressure) can only be found when your doctor does tests from time to time to check your progress.

After taking Lenalidomide Devatis Capsules

Storage

This medicinal product does not require any special temperature storage conditions. Keep your capsules in the original package until it is time to take them.

The expiry date (Exp.) for Lenalidomide Devatis Capsules is stamped on the outer box and the blister label. Do not take Lenalidomide Devatis Capsules after this date, the last day of the month shown.

Keep this medicine where children cannot reach it.

A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop taking this medicine or the expiry date has passed, take any unused Lenalidomide Devatis Capsules to your pharmacist.

Medicines should not be disposed of via wastewater or household waste. These measures will help to protect the environment.

Product description

What it looks like

The capsules are provided in packs. There are four (4) pack sizes available.

A pack with one blister, with seven capsules, giving a total of seven (7) capsules per pack.

A pack with two blisters, each with seven capsules, giving a total of fourteen (14) capsules per pack.

A pack with three blisters, each with seven capsules, giving a total of twenty-one (21) capsules per pack.

A pack with four blisters, each with seven capsules, giving a total of twenty-eight (28) capsules per pack.

Some strengths of Lenalidomide Devatis may not be available as not all strengths are being distributed.

Lenalidomide Devatis 2.5 mg Capsules

Size 4 hard gelatine capsules (length: 14.4 mm) with a blue-green cap and a white body imprinted with "2.5 mg". Both imprints are black. Capsules are filled with white to off-white powder.

Lenalidomide Devatis 5 mg Capsules

Size 2 hard gelatine capsules (length: 17.8 mm) with a white cap and a white body imprinted with "5 mg". Both imprints are black. Capsules are filled with white to off-white powder.

Lenalidomide Devatis 7.5 mg Capsules

Size 2 hard gelatine capsules (length: 17.8 mm) with a pale yellow cap and a white body imprinted with "7.5 mg". Both imprints are black. Capsules are filled with white to off-white powder.

DEVATIS LIMITED Property-Strictly confidential

Page 8 / 9





Module 1.3.2 Consumer Medicine Information (CMI)

Lenalidomide Devatis 10 mg Capsules

Size 0 hard gelatine capsules (length: 21.4 mm) with a blue-green cap and a pale yellow body imprinted with "10 mg". Both imprints are black. Capsules are filled with white to off-white powder.

Lenalidomide Devatis 15 mg Capsules

Size 0 hard gelatine capsules (length: 21.4 mm) with a pale blue cap and a white body imprinted with "15 mg". Both imprints are black. Capsules are filled with white to off-white powder.

Lenalidomide Devatis 20 mg Capsules

Size 0 hard gelatine capsules (length: 21.4 mm) with a blue-green cap and a pale blue body imprinted with "20 mg". Both imprints are black. Capsules are filled with white to off-white powder.

Lenalidomide Devatis 25 mg Capsules

Size 0 hard gelatine capsules (length: 21.4 mm) with a white cap and a white body imprinted with "25 mg". Both imprints are black. Capsules are filled with white to off-white powder.

Ingredients

Active ingredient:

The active ingredient in Lenalidomide Devatis Capsules is lenalidomide.

Other ingredients:

Lactose anhydrous (obtained from bovine milk), microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate

The capsule shell contains gelatine and titanium dioxide and the printing ink contains black iron oxide (E172) and the following additional colourants for

2.5 mg, 10 mg and 20 mg Capsule: indigo carmine (E132) and yellow iron oxide (E172)

7.5 mg Capsule: yellow iron oxide (E172) 15 mg Capsules: indigo carmine (E132)

If you have been told by your doctor that you have an intolerance to certain sugars (for example, lactose), tell your doctor before taking Lenalidomide Devatis Capsules.

Sponsor

DEVATIS LIMITED

45 Yarrow Street, Invercargill 9810, New Zealand

Tel: +64 3 211 0080 Fax: +64 3 211 0079 www.devatis.nz

Date of Preparation

This leaflet was prepared on 12.05.2022.